BACKGROUND: Pancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx. AIM: This study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate. METHODS: We analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls. RESULTS: Most of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients. CONCLUSION: This report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.
- MeSH
- C-peptid krev MeSH
- diabetes mellitus 1. typu epidemiologie etiologie terapie MeSH
- dospělí MeSH
- hodnocení rizik MeSH
- hypoglykemie epidemiologie terapie MeSH
- krevní glukóza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- následné studie MeSH
- přežívání štěpu MeSH
- retrospektivní studie MeSH
- syndrom MeSH
- transplantace Langerhansových ostrůvků * škodlivé účinky metody MeSH
- transplantace slinivky břišní * škodlivé účinky metody MeSH
- výběrové chování MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Transplantace Langerhansových ostrůvků (TxLO) byla v roce 2005 zavedena v Institutu klinické a experimentální medicíny (IKEM) jako potenciálně bezpečnější alternativa transplantace pankreatu (TxP), jež dosud představovala metodu volby u diabetiků 1. typu s konzervativně nezvládnutelným syndromem porušeného vnímání hypoglykemie. Cílem práce je porovnat schopnost obou metod eliminovat závažné hypoglykemie a další komplikace. Transplantaci Langerhansových ostrůvků od zavedení metody v roce 2005 do listopadu 2015 podstoupilo celkem 48 pacientů. Výsledky jsme hodnotili u 22 z nich, u kterých byl přítomen syndrom porušeného vnímání hypoglykemie. Počet transplantovaných ostrůvkových ekvivalentů činil 12 096 (6933−16 705) IEQ/kg, byly podány v místním znecitlivění perkutánně pod radiologickou kontrolou do portální žíly. TxP podstoupilo od roku 1996 44 pacientů. Hodnotili jsme glykovaný hemoglobin (HbA1c), dávky inzulinu, C-peptid lačný a stimulovaný, frekvenci těžkých hypoglykemií a komplikace. Mediány (interquartile range) jsme porovnávali pomocí Wilcoxonova rank testu. Po 1 i 2 letech od TxLO významně klesl HbA1c, byl měřitelný C-peptid, snížila se dávka inzulinu i frekvence hypoglykemií, 18 % příjemců bylo přechodně (maximálně 6 měsíců) bez potřeby inzulinu. Nejčastější komplikací bylo krvácení u 41 % pacientů. Jeden rok po TxP bylo 73 % pacientů bez potřeby inzulinu a hypoglykemií, 2 roky poté pak 68 % pacientů bez inzulinu a hypoglykemií, graftektomie proběhla u 20 % pacientů. Transplantace Langerhansových ostrůvků i transplantace pankreatu vedly k obnově sekrece inzulinu a eliminovaly těžké hypoglykemie. TxP vedla častěji k nezávislosti na inzulinu za cenu závažnějších komplikací. TxLO je méně invazivní metoda, kterou je potřeba dále rozvíjet.
Islet transplantation (ITx) started in 2005 in IKEM as a potentially safer alternative to pancreas transplantation (PTx), which so far had represented the method of choice in type-1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. The aim of the study was to compare these two methods with regard to severe hypoglycemia elimination and to frequency of complications. Up to November 2015 a total number of 48 patients underwent ITx. The results from 22 patients with hypoglycemia unawareness were statistically analyzed. The mean number of transplanted islet equivalents was 12,096 (6,933−16,705) IEQ/kg administered percutaneously in local anesthesia under radiological control to the portal vein. 44 patients underwent PTx from 1996. We evaluated glycated hemoglobin(HbA1c), insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia and complications. Medians (interquartile range) were analyzed using the Wilcoxon signed-rank test. One and two years after ITx, HbA1c decreased, C-peptide became significantly positive, insulin dose and frequency of severe hypoglycemia decreased and 18 % of ITx recipients were temporarily insulin-independent. Bleeding was present in 41 % of patients. One year after PTx, 73 % of patients were insulin and hypoglycemia-free, after two years 68 % of patients were insulin and hypoglycemia-free; graftectomy occurred in 20 % of recipients. Both methods led to restoration of insulin secretion and severe hypoglycemia elimination. PTx made more recipients insulin-independent at the cost of serious complications.
- Klíčová slova
- syndrom porušeného vnímání hypoglykemie,
- MeSH
- C-peptid metabolismus MeSH
- diabetes mellitus 1. typu * chirurgie MeSH
- dospělí MeSH
- glykovaný hemoglobin analýza MeSH
- hypoglykemie diagnóza epidemiologie prevence a kontrola MeSH
- inzulin terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- odběr tkání a orgánů MeSH
- pilotní projekty MeSH
- pooperační komplikace MeSH
- prospektivní studie MeSH
- syndrom MeSH
- transplantace Langerhansových ostrůvků * metody MeSH
- transplantace slinivky břišní * metody MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Publikační typ
- abstrakt z konference MeSH
Sitagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor that exerts an anti-hyperglycaemic effect by preventing degradation of glucagon-like peptide 1 with subsequent β-cell stimulation and potential regeneration. We tested whether sitagliptin therapy in symptomatic non-obese diabetic (NOD) mice would lead to changes in the immune cell profile, improve β-cell survival and induce diabetes remission. Flow cytometry analysis of immune cells in the spleen and peripheral lymph nodes, immunohistology of the pancreas and DPP-IV activity were investigated in diabetic NOD mice, either treated or non-treated with sitagliptin, at 0, 7, 14 and 28 days after hyperglycaemia onset, and in non-diabetic NOD controls. While compared to diabetic controls sitagliptin prevented increase of the CD8+/CD4+ ratio in pancreatic nodes after four weeks (0.443 ± 0.067 vs. 0.544 ± 0.131; P < 0.05), the population of Tregs in lymph nodes increased from day 0 to 28 in both treated and non-treated diabetic groups (8 ± 1.76 vs. 13.45 ± 5.07 % and 8 ± 1.76 vs. 13.19 ± 5.58 %, respectively). The severity of islet infiltration was similar in both diabetic groups and decreased in parallel with β-cell loss. Surprisingly, sitagliptin blocked the DPP-IV activity only temporarily (on day 7, 277.68 ± 89.2 vs. 547.40 ± 94.04 ng/ml in the diabetic control group) with no apparent effect later on. In conclusion, sitagliptin administered after the onset of overt hyperglycaemia in NOD mice had only a marginal immunological effect and did not lead to diabetes remission. Failure to block DPP-IV over time represents an important finding that requires further explanation.
- MeSH
- časové faktory MeSH
- diabetes mellitus 1. typu farmakoterapie imunologie patologie MeSH
- dipeptidylpeptidasa 4 účinky léků MeSH
- inhibitory dipeptidylpeptidasy 4 krev farmakologie terapeutické užití MeSH
- Langerhansovy ostrůvky imunologie patologie MeSH
- lymfatické uzliny účinky léků imunologie patologie MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední NOD MeSH
- myši MeSH
- pyraziny farmakologie terapeutické užití MeSH
- slezina imunologie patologie MeSH
- T-lymfocyty - podskupiny účinky léků imunologie patologie MeSH
- triazoly farmakologie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Publikační typ
- abstrakt z konference MeSH
Labeling of pancreatic islets with superparamagnetic iron oxide (SPIO) nanoparticles enables their post-transplant monitoring by magnetic resonance imaging (MRI). Although the nanoparticles are incorporated into islet cells in culture, little is known about their fate in vivo. We studied the morphology of labeled islets after transplantation, aiming to identify the MRI contrast particles and their relationship to transplantation outcomes. Rat islets labeled with the ferucarbotran were transplanted into the liver or under the kidney capsule of syngeneic and allogeneic rats. After in vivo MRI, morphology was studied by light, fluorescence and transmission electron microscopy. Morphology of syngeneic islets transplanted beneath the kidney capsule vs into the liver was similar. Iron particles were almost completely eliminated from the endocrine cells and remained located in host-derived macrophages surrounding the vital islets for the entire study period. In the allogeneic model, islets lost their function and were completely rejected within nine days following transplantation in both transplant models. However, intercellular transport of the SPIO particles and subsequent MRI findings was different in the liver and kidney. In the liver, the decreasing number of islet-related MRI spots corresponded with clearance of iron particles in rejected islets; in contrast, with renal transplants extensive iron deposits with a high effect on MRI signal persisted in phagocytic cells beneath the capsule. We conclude that MRI detection of the iron contrast agent correlates with islet survival and function in islet transplantation into the liver, while it does not correlate in the case of transplantation beneath the renal capsule.
- MeSH
- barvení a značení MeSH
- dextrany chemie farmakokinetika MeSH
- inbrední kmeny potkanů MeSH
- játra metabolismus MeSH
- kontrastní látky chemie farmakokinetika MeSH
- krysa rodu rattus MeSH
- Langerhansovy ostrůvky cytologie metabolismus MeSH
- ledviny metabolismus MeSH
- magnetická rezonanční tomografie MeSH
- magnetické nanočástice chemie MeSH
- tkáňová distribuce MeSH
- transplantace Langerhansových ostrůvků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Publikační typ
- abstrakt z konference MeSH